Correlates of protection against SARS-CoV-2 in rhesus macaques

Recent studies have reported the protective efficacy of both natural 1 and vaccine-induced 2 – 7 immunity against challenge with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in rhesus macaques. However, the importance of humoral and cellular immunity for protection against infection...

Full description

Saved in:
Bibliographic Details
Published inNature (London) Vol. 590; no. 7847; pp. 630 - 634
Main Authors McMahan, Katherine, Yu, Jingyou, Mercado, Noe B., Loos, Carolin, Tostanoski, Lisa H., Chandrashekar, Abishek, Liu, Jinyan, Peter, Lauren, Atyeo, Caroline, Zhu, Alex, Bondzie, Esther A., Dagotto, Gabriel, Gebre, Makda S., Jacob-Dolan, Catherine, Li, Zhenfeng, Nampanya, Felix, Patel, Shivani, Pessaint, Laurent, Van Ry, Alex, Blade, Kelvin, Yalley-Ogunro, Jake, Cabus, Mehtap, Brown, Renita, Cook, Anthony, Teow, Elyse, Andersen, Hanne, Lewis, Mark G., Lauffenburger, Douglas A., Alter, Galit, Barouch, Dan H.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 25.02.2021
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Recent studies have reported the protective efficacy of both natural 1 and vaccine-induced 2 – 7 immunity against challenge with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in rhesus macaques. However, the importance of humoral and cellular immunity for protection against infection with SARS-CoV-2 remains to be determined. Here we show that the adoptive transfer of purified IgG from convalescent rhesus macaques ( Macaca mulatta ) protects naive recipient macaques against challenge with SARS-CoV-2 in a dose-dependent fashion. Depletion of CD8 + T cells in convalescent macaques partially abrogated the protective efficacy of natural immunity against rechallenge with SARS-CoV-2, which suggests a role for cellular immunity in the context of waning or subprotective antibody titres. These data demonstrate that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in rhesus macaques, and that cellular immune responses may contribute to protection if antibody responses are suboptimal. We also show that higher antibody titres are required for treatment of SARS-CoV-2 infection in macaques. These findings have implications for the development of SARS-CoV-2 vaccines and immune-based therapeutic agents. Adoptive transfer of purified IgG from convalescent macaques protects naive macaques against SARS-CoV-2 infection, and cellular immune responses contribute to protection against rechallenge with SARS-CoV-2.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
D.H.B. designed the study. K.M., J.Y., N.B.M., L.H.T., A.C., J.L., L.P., E.A.B., M.S.G., C.J.D., Z.L., F.N., and S.P. performed the immunologic and virologic assays. C.L., C.A., A.Z., D.A.L., and G.A. performed the systems serology and regression modeling. L.P., A.V.R., K.B., J.Y.-O., M.C., R.B., A.C., E.T., H.A., and M.G.L. led the clinical care of the animals. D.H.B. wrote the paper with all co-authors.
Co-First Authors
Author Contributions
ISSN:0028-0836
1476-4687
1476-4687
DOI:10.1038/s41586-020-03041-6